Epirubicin and Celecoxib in Treating Patients With Hepatocellular Carcinoma
Status:
Completed
Trial end date:
2007-02-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Celecoxib may stop the growth of tumor cells by stopping blood flow to the tumor.
Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop
growing or die. Combining celecoxib with epirubicin may kill more tumor cells.
PURPOSE: This phase I/II trial is studying the side effects and best dose of epirubicin when
given together with celecoxib and to see how well it works in treating patients with
hepatocellular carcinoma (liver cancer).